Therapeutic Drug Monitoring in Children and Adolescents: Findings on Fluoxetine from the TDM-VIGIL Trial

Fluoxetine is the recommended first-line antidepressant in many therapeutic guidelines for children and adolescents. However, little is known about the relationships between drug dose and serum level as well as the therapeutic serum reference range in this age group. Within a large naturalistic obse...

Descripción completa

Detalles Bibliográficos
Autores principales: Frey, Michael, Smigielski, Lukasz, Tini, Elvira, Fekete, Stefanie, Fleischhaker, Christian, Wewetzer, Christoph, Karwautz, Andreas, Correll, Christoph U., Gerlach, Manfred, Taurines, Regina, Plener, Paul L., Malzahn, Uwe, Kornbichler, Selina, Weninger, Laura, Brockhaus, Matthias, Reuter-Dang, Su-Yin, Reitzle, Karl, Rock, Hans, Imgart, Hartmut, Heuschmann, Peter, Unterecker, Stefan, Briegel, Wolfgang, Banaschewski, Tobias, Fegert, Jörg M., Hellenschmidt, Tobias, Kaess, Michael, Kölch, Michael, Renner, Tobias, Rexroth, Christian, Walitza, Susanne, Schulte-Körne, Gerd, Romanos, Marcel, Egberts, Karin Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10534581/
https://www.ncbi.nlm.nih.gov/pubmed/37765171
http://dx.doi.org/10.3390/pharmaceutics15092202

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10534581/
https://www.ncbi.nlm.nih.gov/pubmed/37765171
http://dx.doi.org/10.3390/pharmaceutics15092202

Ejemplares similares